Medtronic Symplicity Renal Denervation System Potentially Cost-Effective and May Reduce Clinical Events in Treatment-Resistant Hypertension

September 17th, 2012 Ronney Shantouf Cardiology, Medicine, News, Radiology, Vascular Surgery

A new article published in the Journal of the American College of Cardiology suggests that the Medtronic renal denervation system, Symplicity, is a cost-effective strategy for treatment-resistant Hypertension. Currently, the Symplicity system is only available for investigational use in the United States. The statistical model used suggests that incorporating Standard of Care medication therapy, including 3 or greater medications, with renal denervation could potentially reduce cardiovascular mortality by 30% and all-cause mortality by 15% when compared to Standard of Care alone.

The study used Framingham Risk Estimates, the Prospective Cardivascular Munster Heart Study risk equations, recent cohort studies, and recent published mortality rates in their model to predict and estimate clinical events.

Renal denervation is a minimally invasive, catheter-based procedure that uses radio-frequency energy to alter the output from nerves within the renal arteries. These nerves, part of the sympathetic nerve system, contribute to the overall regulation of blood pressure.

This is extremely promising for those patients with hard to control hypertension, as this can be a potential avenue to avoid polypharmacy and still remain cost effective. However, further randomized controlled trials (which are on-going) will need to be conducted to better solidify the technology’s clinical impact beyond predictive risk models.

Medtronic news release: Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

Study in Journal of the American College of Cardiology: Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension

SYMPLICITY HTN-3 U.S Clinical Trial info page…

Flashbacks: Medtronic Starts Trial with Symplicity Renal Denervation System for Chronic Heart Failure and Renal Impairment; Medtronic Gets FDA Nod for Renal Denervation Trial

Upcoming conferences

october

18octallday19alldayWorld Congress on Polycystic Ovarian Syndrome and Fertility, 2018Abu Dhabi, UAE

18octallday19alldayManaging Your Complaints and Obstacles in Post-Market Requirements -- Results from Top Medical Device Observations During an InspectionMinneapolis, MN, USA

Event Details

Post-Market activities, Complaint Handling, MDRs, and Recalls are expensive, time consuming, and often lead to more serious financial consequences. Over 80% of FDA Inspection target observations for lack of compliance in these areas.

By attending this seminar, you will discover:

How to overcome one of the biggest obstacles device manufacturers face
How the FDA expects you to develop and implement proper handling of complaints reportable or non-reportable, product complaint handling and documentation
How and when to file Medical Device Reports (MDR), effective and appropriate communication with the appropriate regulatory agencies in the event of a recall.
How to conduct a correction and removal actions to avoid a recall crisis, including required recordkeeping, expectation from FDA and other regulatory agencies in the event of a recall and key factors in implementing and maintaining compliance with the regulations and real life experiences of FDA.

**New course materials have been added, updated content will include:

Creating Standard Operating Systems (SOPs) for Post-Market Quality Systems and
What to expect from the changes in ORA with Inspection Structure Realignment

This Seminar will have you stop spinning your wheels with nonessential activities, and leave you with a comprehensive learning package that only Rita Hoffman, a former FDA CDRH Recall Branch Chief with experience across the device, drug and veterinary industries can provide.

Spend one and a half days in an interactive course led by Ms. Rita Hoffman, Former FDA CDRH Recall Branch Chief with over 36 years with FDA and leading Industry Expert, who will provide the participants with tools to minimize risk of regulatory enforcement actions.

Time

october 18 (Thursday) - 19 (Friday)

Organizer

Compliance Online 80068SEM

Learn More

Calendar GoogleCal

18octallday19allday18th Global Ophthalmology, Optometry and Glaucoma Conference, 2018Helsinki, Finland

18octallday19alldayBiology and Pathology of Infectious Disease Conference, 2018Helsinki, Finland

18octallday19allday14th Global Biomarkers Summit, 2018Amsterdam, Netherlands

22octallday23alldayInternational Conference on Breast Cancer, 2013Vancouver, British Columbia, Canada